Home | AMVUTTRA® (vutrisiran)
AMVUTTRA® (vutrisiran) is a prescription medicine given once every 3 months by a healthcare professional to treat the polyneuropathy caused by hATTR amyloidosis in adults.
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), …
Mar 20, 2025 · Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran), OXLUMO ® (lumasiran), and Leqvio ® …
For Healthcare Professionals | AMVUTTRA® (vutrisiran) HCP
AMVUTTRA® (vutrisiran) is the first and only silencer approved for ATTR-CM and hATTR-PN in adults. See safety info on low vitamin A levels and PI.
Vutrisiran - Wikipedia
Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. [7][5][8] It …
Home | AMVUTTRA® (vutrisiran) | Alnylam Assist®
Alnylam Assist® provides education, support services and resources to help you and your family throughout your treatment with AMVUTTRA® (vutrisiran).
Orsini Specialty Pharmacy Selected as a Limited Distribution …
Oct 19, 2023 · Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, has been chosen by Alnylam Pharmaceuticals as a specialty pharmacy partner for AMVUTTRA™ …
Amvuttra (vutrisiran) FDA Approval History - Drugs.com
Mar 24, 2025 · FDA approval history for Amvuttra (vutrisiran) used to treat Hereditary Amyloidosis, Cardiomyopathy of Transthyretin-Mediated Amyloidosis. Supplied by Alnylam …
nts as amyloid deposits AMVUTTRA is an RNAi to silence TTR messenger RNA and reduce the production of TTR in the liver, which results in a reduction of serum TTR protein and the …
How AMVUTTRA Works | AMVUTTRA® (vutrisiran)
Explore how AMVUTTRA® (vutrisiran), a prescription medicine, works in adults. See safety info on low vitamin A levels and PI.
AMVUTTRA™ Vutrisiran 25 mg / 0.5 mL Injection 1 mL
Order AMVUTTRA™ Vutrisiran 25 mg / 0.5 mL Injection 1 mL by Alnylam Pharmaceuticals Inc 71336100301